ProfileGDS5678 / 1435188_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 39% 39% 26% 41% 41% 53% 43% 39% 45% 39% 45% 37% 40% 40% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9358439
GSM967853U87-EV human glioblastoma xenograft - Control 22.8969639
GSM967854U87-EV human glioblastoma xenograft - Control 32.6023626
GSM967855U87-EV human glioblastoma xenograft - Control 42.9003941
GSM967856U87-EV human glioblastoma xenograft - Control 52.9048341
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3816853
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0733243
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8743139
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0290345
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.879739
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0528545
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8006337
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9163140
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.913540